Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

N/A

4(57.1%)

Phase 3

1(14.3%)

Phase 1

1(14.3%)

Phase 4

1(14.3%)

7Total

N/A(4)

Phase 3(1)

Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07561450Phase 4Not Yet Recruiting

Demodex Blepharitis in Scleral Lens Wearers

Role: lead

NCT07195721Recruiting

The Effect of PROSE or Scleral Lenses on Mental Health

Role: lead

NCT04313725Not ApplicableTerminated

Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease

Role: collaborator

NCT04918823Phase 1Completed

Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device

Role: lead

NCT04308941Not ApplicableCompleted

Tonometry Precision and Accuracy During PROSE Scleral Lens Wear: A Pilot Study

Role: lead

NCT04649177Not ApplicableCompleted

Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting

Role: lead

NCT04735510Phase 3Withdrawn

Novel Use of Restasis and PROSE Devices

Role: lead

NCT03647046Not ApplicableCompleted

Custom Anterior Surfacing of Scleral Lens for Vision Quality Improvement in Patients With Keratoconus

Role: collaborator

All 8 trials loaded